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Summary
 Background Oxidants can act at several stages of malignant transformation. To protect against 
toxic effects of oxidants and to modulate physiological effects of their action or-
ganisms have developed antioxidant defence systems. Plasma total antioxidant 
activity (TAS) measures peroxyl-scavenging capacity of the extracellular antioxi-
dant system.
 Aim The goal of this pilot study was to evaluate the plasma total antioxidant status in 
breast cancer women in relation to lymph node metastases and HER-2/neu ex-
pression.
 Materials/Methods Newly diagnosed consecutive breast cancer patients (n=26) were recruited before 
any treatment and matched with controls (n=24) randomly selected from benign 
breast disease patients. Cancer progress was established according to lymph node 
involvement: No or N+. HER-2/neu was considered as either negative (0 or 1+) 
or positive (2+ or 3+). The plasma total antioxidant status (TAS) was measured by 
colorimetric test (RANDOX). HER-2/neu oncogene expression was determined 
in breast cancer tissue using the immunohistochemical method (Hercep Test).
 Results The study demonstrated a signiﬁ cant decrease in the mean TAS level (mmol/L) 
in the breast cancer group (1.42±0.22) in comparison to the control group 
(1.56±0.18; P<0.01). The mean TAS concentration was found not to differ sig-
niﬁ cantly between breast cancer subgroups in relation to the progress of the dis-
ease. Although the mean TAS concentration was not signiﬁ cantly different in re-
gard to the HER-2/neu expression, there was a tendency observed towards higher 
TAS in the HER-2/neu negative subgroup (1.46±0.20) than in the HER-2/neu 
positive one (1.41±0.25).
 Conclusions The results of the study suggest increased consumption of plasma antioxidants 
in response to enhanced oxidants production in breast cancer patients. Changes 
in TAS level do not seem to correspond with the progress of the malignancy but 
might be related to HER-2/neu expression.
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BACKGROUND
Oxidants, i.e. reactive oxygen and nitrogen spe-
cies, generated during both metabolic and in-
ﬂ ammatory processes can attack DNA bases or 
deoxyribose residues to produce damaged bases 
and strand breaks. Alternatively, oxidants can ox-
idize protein and lipid molecules, and thus pro-
duce intermediates that react with DNA to form 
adducts. This damage leads eventually to mu-
tation or apoptosis. Oxidants can act at several 
stages of malignant transformation. They induce 
permanent DNA sequence changes and can trig-
ger epigenetic pathways which participate in the 
regulation of growth and differentiation [1]. On 
the other hand, cancer cells are reported to pro-
duce large amounts of reactive oxygen species, 
especially hydrogen peroxide [2].
To protect against toxic effects of oxidants and 
to modulate physiological effects of their action 
organisms have developed antioxidant defence 
systems. Both extracellular (mostly proteins and 
low molecular weight substances) and intracel-
lular (mostly enzymes) defence systems consist 
of multiple interdependent components. A ﬁ ne 
balance among many antioxidants appears to be 
more important for the overall protective capac-
ity of the defence system than the activity or con-
centration of a single constituent [3].
Oxidative stress is deﬁ ned as an imbalance be-
tween oxidants and antioxidants favouring reac-
tive oxygen and nitrogen species.
Plasma total antioxidant activity (TAS) measures 
peroxyl-scavenging capacity of the extracellu-
lar antioxidant system, comprised of sulphydryl 
groups (mostly albumin), urate, ascorbate, caro-
tenoids, retinol, á-tocopherol, bilirubin and pro-
teins. TAS reﬂ ects residual antioxidant capacity 
after the consumption of reactive oxygen spe-
cies [4,5]. To the best of our knowledge, there 
are only a few reports concerning oxidant-anti-
oxidant status stress in regard to breast cancer 
progress or to HER-2/neu expression.
AIM
The goal of this pilot study was to evaluate the 
plasma total antioxidant status in breast cancer 
women in relation to lymph node metastases and 
HER-2/neu expression.
MATERIALS AND METHODS
Materials
Newly diagnosed consecutive breast cancer pa-
tients were recruited before any treatment and 
matched with controls randomly selected from 
benign breast disease patients admitted to the 
1st Ward of Surgical Oncology, Great Poland 
Cancer Centre in Poznań. On the basis of com-
plete clinical examination those with the follow-
ing conditions – alcohol abuse, chronic liver and 
renal disorders, any inﬂ ammatory process, diabe-
tes mellitus, advanced atherosclerosis of any loca-
tion, malabsorption or malnutrition syndrome, 
and malignancy other than breast cancer – were 
excluded from the study. The studied individu-
als were not taking any micronutrient supple-
mentation. Smokers were asked not to smoke 
overnight before the blood collection. In the 
analyzed group there were 50 patients: 26 with 
breast carcinoma and 24 with benign breast dis-
eases (Table 1).
Blood samples were collected from women with 
breast cancer and female controls after overnight 
fasting and stored at –80°C until assayed.
Cancer progress was established as: local (with-
out any lymph nodes involved, No, and without 
any distant metastases, Mo) and meta (with the 
presence of lymph nodes involved and without 
any distant metastases, Mo). HER-2/neu was 
considered as either negative (0 or 1+) or posi-
tive (2+ or 3+).
All patients were informed of the study pur-
pose and gave written consent. The reported 
study was approved by the Ethics Committee of 
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Poznań University of Medical Sciences, Poznań, 
Poland.
METHODS
The plasma total antioxidant status (TAS) was 
measured with the ABTS reagent (2,2’-azino-di-
[3-ethylbenzthiazoline sulphate]) by colorimetric 
test (RANDOX Laboratories Ltd, Crumlin, United 
Kingdom) on StatFax™ 1904 Plus (Awareness 
Technology, Inc, Palm City, FL, USA).
HER-2/neu oncogene expression was deter-
mined routinely in breast cancer tissue using the 
immunohistochemical method (Hercep Test, 
DAKOCytomatin Company, Carpinteria, Ca, USA) 
in Great Poland Cancer Centre, Poznań.
Statistical analysis was performed using Statistica 
6.0 for Windows (StatSoft). The results are ex-
pressed as means ± standard deviations. The distri-
bution of values was veriﬁ ed by Shapiro-Wilk test. 
The comparisons between groups and subgroups 
were performed using non-parametric Mann-
Whitney test. The statistical signiﬁ cance for the 
differences was accepted at the level P<0.05.
RESULTS
The study has demonstrated a signiﬁ cant decrease 
in the mean TAS level in the breast cancer group 
in comparison to the control group. The mean 
TAS concentration was found not to differ signif-
icantly between breast cancer subgroups in rela-
tion to the progress of the disease. Although the 
mean TAS concentration was not signiﬁ cantly dif-
ferent in regard to HER-2/neu expression, there 
was a tendency observed towards higher TAS in 
the HER-2/neu negative subgroup than in the 
HER-2/neu positive one (Table 2).
DISCUSSION
The present study revealed changed plasma total 
antioxidant status in women with breast cancer 
as has already been reported. Decreased plasma 
TAS level in patients affected with malignancy 
suggests enhanced consumption of plasma anti-
oxidants in response to increased production of 
reactive oxygen species. Thus, the ﬁ nding sup-
ports the hypothesis of oxidative stress involve-
ment in malignant process in the breast.
The results of other studies showed that the lev-
els of superoxide radical and malonyldialdehyde 
Study group/subgroup Number of patients
Breast cancer group 26
Age 54.7±8.0
Menopausal status
 pre
 post
 HRT
4
22
7
Histology type
 ductal
 lobular
24
2
Clinical stage:
 a) Dcis
  T1
  T2
 b) N0 (local)
  N+ (meta)
3
16
7
18
8
Hormonal receptors status
 ER+
 ER–
 PG+
 PG–
25
1
24
2
Smoking history (positive) 4
Control group 24
Age 58.8±9.4
Menopausal status
 pre
 post
 HRT
8
16
8
Histology type
 fi broadenoma
 mastopathia fi brosa and cystica
 adenosis sclerosans
 hyperplasia ductalis
8
11
2
3
Smoking history (positive) 5
Table 1. Clinical characteristics of patient groups: with breast 
cancer and benign breast disease (control group).
Study group/subgroup TAS [mmol/L]
Breast cancer group
local (No)
meta (N+)
HER-2/neu negative (–)
HER-2/neu positive (+)
 1.42±0.22*
 1.42±0.23
 1.42±0.20
 1.46±0.20
 1.41±0.25
Control group  1.56±0.18
Table 2. Plasma total antioxidant activity (TAS) in breast cancer 
and benign breast disease (control) groups, also in relation to 
progress of the malignancy and HER-2/neu expression. The results 
are expressed as means ±SD.
* signifi cantly diff erent from the control group, P<0.01.
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(MDA) – one of the lipid peroxidation markers 
– and the activities of some antioxidant enzymes 
(SOD – superoxidae dismutase, GPx – glutathione 
peroxidase, and GRx – glutathine reductase) in 
blood of patients with breast cancer were higher 
than in the controls, while the levels of vitamin C 
and both reduced and oxidized glutathione were 
decreased. The ﬁ ndings also conﬁ rm increased 
consumption of plasma antioxidant micronutri-
ents and on the other hand upregulation of eryth-
rocyte antioxidant enzymes activities, which does 
not protect macromolecules (e.g. lipids) from the 
consequences of enhanced oxidative stress [6]. 
Similarly, a study on oxidant-antioxidant status in 
breast cancer tissue revealed increased concen-
tration of lipid peroxidation markers (MDA, hy-
droperoxides and conjugated diens) along with 
SOD and GPx activities in comparison to adja-
cent normal tissues and to ﬁ broadenoma [7,8]. 
Moreover, higher concentrations of plasma to-
tal antioxidant status (measured with a different 
method than in the present study) and plasma 
micronutrients or metabolite with strong antioxi-
dant properties, e.g. b-carotene, retinoid and bi-
lirubin, were already observed to be associated 
with reductions in breast cancer risk [9].
The ﬁ ndings of the present investigation failed 
to demonstrate any difference in the plasma 
TAS level between the localized breast cancer 
subgroup and that with lymph nodes involved. 
Similarly, F. Tas et al. reported that tissue oxi-
dant-antioxidant proﬁ le did not differ between 
breast cancer patients of various stages of the ma-
lignancy: I and II versus III and IV [7]. On the 
contrary, changes in tissue oxidant-antioxidant 
status were observed to be more pronounced in 
clinical stage III than in I and II [8]. The above 
discrepancies might result from various types of 
oxidative stress markers investigated and the rel-
atively small number of patients.
The present research showed no signiﬁ cant 
changes in plasma TAS level in regard to 
HER-2/neu expression, although a tendency 
towards lower TAS level in HER-2/neu positive 
(+) in comparison to HER-2/neu negative (–) 
was found. An increase in GPx activity in HER-
2/neu positive (+) compared to HER-2/neu neg-
ative (–) was described in breast cancer tissue, 
while other oxidant-antioxidant status markers 
(MDA, SOD, CAT-catalase) remained unchanged 
[7]. The above ﬁ ndings may suggest that oxida-
tive stress might be related to HER-2/neu ex-
pression, and thus there is a need for further 
investigation.
CONCLUSIONS
The results of the study suggest increased con-
sumption of plasma antioxidants in response to 
enhanced oxidant production in breast cancer 
patients. Changes in TAS level do not seem to 
correspond with the progress of the malignancy 
but might be related to HER-2/neu expression. 
Future research is needed to evaluate plasma 
TAS level along with oxidative damage markers 
to give better insight into oxidant-antioxidant 
imbalance in breast malignancy and on larger 
groups of patients.
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